Compare Crispr Therapeutics AG (CRSP) vs Kingsoft Cloud Holdings Limited (KC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Kingsoft Cloud Holdings Limited — how do they compare? Crispr Therapeutics AG trades at $53.85 (market cap $5.23B), while Kingsoft Cloud Holdings Limited trades at $11.69 (market cap $3.53B). The key difference: Crispr Therapeutics AG is the larger of the two by market cap. Which is the better fit depends on your goals.
| CRSP | KC | |
|---|---|---|
Market Cap | $5.23B | $3.53B |
Sector | Health | Technology |
52-Week High | $76.78 | $18.21 |
52-Week Low | $44.34 | $8.58 |
Enterprise Value | $3.65B | $3.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
Kingsoft Cloud (KC) trades at $11.75, down 1.76% today, with a bullish technical signal supported by moving averages. The company shows strong revenue growth trends (37% YoY in Q1 2026) and has beaten EPS estimates for three consecutive quarters, though it remains unprofitable with a -9.39% net margin. Recent news highlights AI-driven growth momentum, with AI cloud billing now exceeding half of public cloud revenue.
The outlook is cautiously optimistic with 70% analyst buy ratings, but profitability challenges and significant capital expenditures pose risks. The stock's valuation appears reasonable with P/S of 2.22, though negative ROE and ROA indicate operational inefficiencies that need addressing for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Kingsoft Cloud Holdings Limited
Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.
Read more on KC →
